SMS Pharmaceuticals Reports Strong PAT and EPS Amid Rising Interest Expenses in June 2025

SMS Pharmaceuticals, a microcap company in the Pharmaceuticals & Biotechnology industry, has recently reported its financial results for the quarter ending June 2025. The evaluation changes reflect a notable shift in the company's score, which has seen a revision in its assessment over the past three months.
The financial data reveals several positive aspects for SMS Pharmaceuticals. The Profit After Tax (PAT) reached Rs 20.49 crore, marking the highest figure in the last five quarters, indicating a favorable near-term PAT trend. Additionally, the Earnings per Share (EPS) also peaked at Rs 2.31 during this period, suggesting an increase in profitability and enhanced earnings for shareholders. Furthermore, the company reported its highest cash and cash equivalents at Rs 41.59 crore over the last six half-yearly periods, indicating an improvement in short-term liquidity. The Debt-Equity Ratio has also reached its lowest point at 0.49 times, reflecting a reduction in borrowing relative to equity capital.

Conversely, there are challenges noted in the financial results. The Operating Profit to Interest ratio has fallen to 6.74 times, the lowest in the last five quarters, indicating a decline in the company's ability to manage interest payments. Additionally, interest expenses have risen to Rs 5.84 crore, the highest in the last five quarters, which points to increased borrowing costs.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.